Cargando…
Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy
Bcr-Abl inhibitors paved the way of targeted therapy epoch. Imatinib was the first tyrosine kinase inhibitor to be discovered with high specificity for Bcr-Abl protein resulting from t(9, 22)-derived Philadelphia chromosome. Although the specific targeting of that oncoprotein, several Bcr-Abl-depend...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6011351/ https://www.ncbi.nlm.nih.gov/pubmed/29925402 http://dx.doi.org/10.1186/s13045-018-0624-2 |